Company News: Curetis Reports Results of the Annual General Meeting Held on June 27, 2019

– All proposed AGM resolutions approved by shareholders

Curetis N.V. (the “Company” and together with its subsidiaries “Curetis“), a developer of next-level molecular diagnostic solutions, today  reported the results of its Annual General Meeting (“AGM”) held in Amsterdam on June 27, 2019.

The Company’s shareholders approved all proposed resolutions and items on the agenda of the AGM. Johannes Bacher, COO of Curetis, has been re-elected as Curetis N.V. Management Board member for a period of three years. 
In addition to this management board appointment, the supervisory board members William E. Rhodes III, Mario Crovetto, and Prabhavathi Fernandes, Ph.D., were re-elected for a further term of two years, respectively. Dr. Rudy Dekeyser was re-elected to the supervisory board for another one-year term. Furthermore, the management board was designated as the company body authorized to issue new shares or to grant rights to subscribe for shares in relation to strategic capital raising(s) and to not limit or exclude pre-emption rights on these shares.
“We are pleased that all proposed AGM resolutions have been approved by our shareholders with resounding majorities, giving the management board and the supervisory board the flexibility to further drive the strategic and commercial development of the Company,” said Oliver Schacht, CEO of Curetis. “In particular, the access to various authorized capitals, one of which is specifically for use in the context of strategic partnerships, may become very helpful in structuring some of the strategic licensing or partnering deals we are currently negotiating and evaluating.”
The Curetis N.V. 2019 AGM meeting minutes, detailed voting results as well as further information will be reported on Curetis’ website at: